A multicentre open-label phase IIa study with escalating dose of MS1819-SD, to investigate the efficacy and safety of a Yarrowia lipolytica lipase preparation for the compensation of exocrine pancreatic insufficiency caused by chronic pancreatitis and/or distal pancreatectomy.

Trial Profile

A multicentre open-label phase IIa study with escalating dose of MS1819-SD, to investigate the efficacy and safety of a Yarrowia lipolytica lipase preparation for the compensation of exocrine pancreatic insufficiency caused by chronic pancreatitis and/or distal pancreatectomy.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Lipase (Primary)
  • Indications Exocrine pancreatic insufficiency; Pancreatitis
  • Focus Adverse reactions
  • Acronyms MS1819-SD
  • Most Recent Events

    • 11 Apr 2017 AzurRx continues to expect completion of this Phase IIa trial in 3Q17, according to a company media release.
    • 11 Apr 2017 Early results published in the an AzurRx BioPharma media release.
    • 21 Dec 2016 According to an AzurRx BioPharma media relase, first three patients have been enrolled in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top